An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.

Trial Profile

An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Severe Chronic Pain Due to Osteoarthritis of the Knee Taking WHO Step III Analgesics But Showing a Lack of Tolerability.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2013

At a glance

  • Drugs Tapentadol (Primary)
  • Indications Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 May 2012 According to the European Clinical Trials Database, this trial is completed in the United Kingdom (Jun 2010), Germany (Aug 2010) and Denmark, and is still recruiting in Spain. According to the ClinicalTrials.gov record, this trial has been discontinued.
    • 02 May 2012 New source identified and integrated (European Clinical Trials Database).
    • 13 Dec 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top